Chemical Compound

Noopept

N-phenylacetyl-L-prolylglycine ethyl ester

Evidence TierDWADA NOT PROHIBITED

tuneTypical Dose

20 mg/day was reported in one stroke cohort

watchEffect Window

Weeks to months in available studies. Preclinical signal in short exposure models.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Noopept is a peptide-like synthetic nootropic with a small, regionally concentrated clinical literature in cognitive-impairment populations and no good evidence in healthy adults.

The human evidence base is largely Russian-language and methodologically limited, with most studies focused on vascular, post-stroke, or post-traumatic cognitive symptoms rather than healthy performance enhancement. Preclinical work does add neurotrophic, antioxidant, and tau-related mechanistic interest, but that has not translated into good-quality evidence for healthy adult memory or focus benefits.

Dipeptide nootropic with uncertain human mechanistic specificity. Preclinical studies suggest antioxidant and neuroprotective effects.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Signal-level improvement in some cognitive impairment settings, primarily post-stroke and post-traumatic contexts.

Secondary Outcomes

  • EEG pattern shifts in older clinical reports.
  • Preclinical reductions in cellular injury markers.

Safety

Contraindications and Interactions

Contraindications

  • Pregnancy
  • Lactation
  • Severe hepatic or renal disease
  • Active psychosis
  • Unstable cardiovascular disease

Side effects

  • Headache
  • Irritability
  • Insomnia
  • GI upset

Interactions

  • CNS-active compounds
  • Sedatives
  • Stimulants

Avoid if

  • Minor psychiatric instability
  • Active seizure disorder
  • Poor medication oversight capacity

Evidence

Study-level References

noopept-SRC-001Prospective cohort/open clinical follow-up
Sourceopen_in_new

A V Amelin et al. 2011. "Noopept in the treatment of mild cognitive impairment in patients with stroke." Zh Nevrol Psikhiatr Im S S Korsakova. PMID: 22500312.

Population: Adults with stroke and mild cognitive impairment

Dose protocol: 20 mg/day during 2 months within a 12-month observational framework

Key findings: Reported improved cognitive scores in the noopept arm. Sample and reporting quality limit certainty.

Notes: Useful directionally, but not a modern double-blind high-rigor anchor.

Paper content

Reported improved cognitive scores in the noopept arm; sample and reporting quality limit certainty.

noopept-SRC-002Clinical Trial (regional publication, abstract-limited)
Sourceopen_in_new

V K Bochkarev et al. 2008. "Clinical and electroencephalographic characteristic of noopept in patients with mild cognitive impairment of posttraumatic and vascular origin." Zh Nevrol Psikhiatr Im S S Korsakova. PMID: 19008801.

Population: Adults with posttraumatic/vascular cognitive disorders

Dose protocol: Study protocol details in original report. No robust comparative meta-grade protocol

Key findings: EEG pattern shifts (alpha/beta increase, delta reduction) were reported.

Notes: Neurophysiologic outcomes are supportive but not definitive clinical endpoints.

Paper content

EEG pattern shifts (alpha/beta increase, delta reduction) were reported.

noopept-SRC-003Comparative clinical trial (old regional trial)
Sourceopen_in_new

G G Neznamov, E S Teleshova. 2009. Comparative studies of noopept and piracetam in mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neurosci Behav Physiol. PMID: 19234797, DOI: 10.1007/s11055-009-9128-4.

Population: Adults with organic cognitive disorders

Dose protocol: Piracetam comparator with lower nominal dose description in historical text

Key findings: Reported positive signal in noopept arm relative to historical comparator framework.

Notes: Poorly accessible full methods and outcomes for contemporary confidence grading.

Paper content

Reported positive signal in noopept arm relative to historical comparator framework.

noopept-SRC-004Preclinical in vitro cellular study
Sourceopen_in_new

Rita U Ostrovskaya et al. 2014. Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model. J Biomed Sci. PMID: 25096780, DOI: 10.1186/s12929-014-0074-2, PMCID: PMC4422191.

Population: AD-relevant cellular model

Dose protocol: Cellular concentrations around micromolar range. No human dose mapping

Key findings: Reduced tau-hyperphosphorylation and injury markers in treated cells.

Notes: Strong mechanistic signal in vitro, not equivalent to clinical efficacy.

Paper content

Reduced tau-hyperphosphorylation and injury markers in treated cells.

Guides

Setup

Help